DNL952
DNLI-J-0001
Phase 1 small_molecule active
Quick answer
DNL952 for Late-onset Pompe Disease is a Phase 1 program (small_molecule) at Denali Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Denali Therapeutics
- Indication
- Late-onset Pompe Disease
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active